GlassScriptPhysician profile
Nota A Hunter
NPI 1598790503
$2,540.37
in general payments reported to CMS, 2019-2025
30 companies · $420 in 2025
The $420 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $710 · 2021: $331 · 2022: $216 · 2023: $385 · 2024: $145 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $950.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $950.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $582.83 | 2019-2021 | |
| Novo Nordisk INC | $366.40 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $246.12 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.48 | 2020-2023 | |
| Amarin Pharma, INC. | $185.56 | 2019-2020 | |
| Lilly USA, LLC | $163.06 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Inspire Medical Systems, INC. | $124.74 | 2023 | Inspire |
| Pfizer INC. | $112.57 | 2019-2025 | |
| Boston Scientific Corporation | $79.73 | 2020-2021 | |
| Globus Medical, INC. | $43.53 | 2025 | Senza |
| Abbott Laboratories | $37.62 | 2022-2023 | Freestyle Libre 3 |
| Sanofi Pasteur INC. | $37.15 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $36.30 | 2022-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Allergan, INC. | $35.24 | 2020 | |
| Madrigal Pharmaceuticals | $30.71 | 2025 | Rezdiffra |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $26.61 | 2020 | |
| Hologic Sales and Service, LLC | $23.36 | 2025 | Thinprep 2000 Processor |
| Dynavax Technologies Corporation | $21.47 | 2025 | Heplisav-B |
| Xeris Pharmaceuticals, INC. | $20.41 | 2025 | Gvoke Hypopen |
| Genentech USA, INC. | $19.04 | 2019 | |
| Corcept Therapeutics | $17.72 | 2025 | Korlym |
| Si-Bone, INC. | $17.12 | 2019 | |
| Exact Sciences Corporation | $16.61 | 2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $15.17 | 2020 | |
| Pacira Therapeutics, INC. | $14.89 | 2020 | |
| Dexcom, INC. | $14.15 | 2023 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $13.71 | 2019 | |
| Astellas Pharma US INC | $13.49 | 2019 | |
| Scilex Pharmaceuticals INC. | $11.84 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nota Hunter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.